TelePeptide

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded GLP-1 medicationCompounded · not FDA-approved
• TirzepatideType not stated

What they publish

TelePeptide publishes 1 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Pricing was not published on the page we captured

Medication cost

Not publicly disclosed on the pages we captured.

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Runs a programme specifically for women with PCOS, alongside general medical weight loss.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Not publicly disclosed on the pages we captured.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Cites specific published cohort data with sample size and outcome, rather than vague 'clinically proven' language. That is a meaningfully higher standard of citation than almost anything else in this directory.
• PCOS is a genuine clinical use case where GLP-1s have supporting evidence for insulin sensitivity and androgen markers, and a dedicated programme is reasonable.
• Also offers NAD+ and sermorelin peptide programmes. Peptides sold outside approved indications are a separate and far less regulated category.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Real-world cohort data is weaker than randomised trial evidence, though citing it specifically is still better practice than most.
• Establish pricing, which was not published.
• Evaluate any peptide offering separately from the GLP-1 programme.